Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price gapped down prior to trading on Monday. The stock had previously closed at $5.91, but opened at $5.53. Valneva shares last traded at $5.47, with a volume of 1,748 shares changing hands.

Wall Street Analyst Weigh In

VALN has been the subject of several research analyst reports. TD Cowen started coverage on shares of Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research report on Monday, September 14th. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Valneva currently has an average rating of “Reduce” and an average target price of $9.30.

Valneva Stock Performance

The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The stock has a market cap of $521.42 million, a price-to-earnings ratio of -2.60 and a beta of 1.53. The stock’s 50-day moving average is $6.35 and its 200 day moving average is $5.82.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The company had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million. Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. As a group, analysts predict that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current fiscal year.

Valneva Company Profile

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.